Silicosis Clinical Trial
Official title:
Silicosis-harnessing New Ideas to Conquer the Re-emergence of an Ancient Lung Disease
NCT number | NCT05546944 |
Other study ID # | SHIELD |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 16, 2022 |
Est. completion date | December 2024 |
An observational cohort study to derive biomarkers which are able to more accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All workers with a history of significant engineered stone exposure will be potentially eligible. Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
Australia | The Prince Charles Hospital | Brisbane | Queensland |
Lead Sponsor | Collaborator |
---|---|
The University of Queensland | Austin Hospital, Melbourne Australia, Royal Prince Alfred Hospital, Sydney, Australia, The Alfred, The Prince Charles Hospital |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the SHIELD study primary outcome is to build up knowledge gap to accurately diagnose silicosis, as well as predict disease progress, assess response to treatment, hasten therapeutic discovery in 12 months. | Establish the SHIELD cohort and associated lung fluid, tissue and blood biobank from well phenotyped RCS-exposed workers identified via the screening programs.
Utilise advanced microscopy, 'omic platforms and single cell RNA sequencing (scRNAseq) alongside conventional laboratory techniques, to identify and validate candidate lung and blood biomarkers associated with disease and disease progression at 12 months. To evaluate associations between baseline characteristics, biomarkers and progression of disease in the full cohort. |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01329003 -
DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)
|
N/A | |
Not yet recruiting |
NCT01338064 -
Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)
|
N/A | |
Recruiting |
NCT04161014 -
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
|
Phase 2 | |
Recruiting |
NCT05118256 -
Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis
|
Phase 2 | |
Completed |
NCT02430259 -
Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
|
Phase 3 | |
Recruiting |
NCT06403800 -
Silicosis and Silicotuberculosis Among Small Scale Gemstone Miners in Northern Tanzania
|
||
Not yet recruiting |
NCT06011785 -
Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil
|
Early Phase 1 | |
Not yet recruiting |
NCT05402176 -
The SHIELD Whole Lung Lavage Study
|
||
Completed |
NCT02794701 -
Comprehensive Risk Assessment of People With Silicosis: A Population-based Study
|
||
Completed |
NCT01977131 -
Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis
|
Phase 1/Phase 2 | |
Completed |
NCT00005280 -
Specialized Center of Research in Occupational and Immunologic Lung Disease
|
N/A | |
Recruiting |
NCT05538299 -
Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials
|
||
Completed |
NCT01725971 -
Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis
|
N/A | |
Recruiting |
NCT06090370 -
Reducing Silica Exposure Among Brick Kiln Workers in Nepal
|
N/A | |
Completed |
NCT04205708 -
Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma
|